| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2851024 | American Heart Journal | 2010 | 7 Pages |
Abstract
This phase 1 study from the United States confirms the ongoing safety profile of BMC administration in patients following STEMI. The improvement in LV ejection fraction at 6 months by cMRI in the cell therapy group was not different than the placebo group. However, BMC administration had a favorable effect on LV remodeling at 6 months.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jay H. MD, David H. MD, Karen RN, Beth C. RN, Rachel E. RN, Nancy BS, Diane BS, John R. MD, Vikrant BS, Ross BS, Timothy D. MD,